Embed Size (px)
Citation preview
Resumen II: Nuevos enfoques terapéuticos y preventivos. PrEP
Arkaitz Imaz Unitat de VIH i ITS
Servei de Malalties Infeccioses Hospital Universitari de Bellvitge
Barcelona, Auditori de La Pedrera, 21 de Febrero de 2017
Agenda
- Nuevas estrategias de TAR
- Concentraciones de ARV y adherencia al TAR
- Interacciones farmacológicas
- TAR y Reservorios
- “Home testing” y “same-day ART”
- PrEP
- TAF
- Babotegravir LA
- Anticuerpos neutralizantes
- Eficacia de la PrEP fuera de los ensayos clínicos
Randomized, open-label, phase IV study
Objective: to compare dual therapy (DT) with
DRV/RTV (800/100 mg) FDC, plus 3TC (300
mg), to triple therapy (TT) with DRV/RTV
(800/100 mg) plus 3TC/TDF (300/300mg), FDC
in treatment-naïve HIV-1 infected patients.
Primary endpoint: proportion of patients with
viral load (pVL) <50 copies/mL at week 48 (FDA
snapshot -ITTe analysis).
Figueroa MI, et al. # 489
Figueroa MI, et al. # 489
Eron J, et al. # 502
Eron J, et al. # 502
Eron J, et al. # 502
Gandhi M, et al. # 24
Gandhi M, et al. # 24
Gandhi M, et al. # 24
Cerrone M, et al. # 28LB
Cerrone M, et al. # 28LB
Cerrone M, et al. # 28LB
Cerrone M, et al. # 28LB
I.C. TFV-DP
concentrations were
76% higher when
TAF+RIF than with
TDF alone
Cerrone M, et al. # 28LB
Elliot E, et al. # 468
Concentrations of DTG during co-administration with DRV/c decreased by 10%
Concentrations of DRV during co-administration with DTG decreased by 7%
GM minimum concentrations (C24) stayed well above the PA IC90 (DTG) and EC90 (DRV) at all time points
Fletcher CV, et al. # 27
Fletcher CV, et al. # 27
Fletcher CV, et al. # 27
Morón-López S, et al. # 501
Morón-López S, et al. # 501
Rasmussen TA, et al. # 71
Rasmussen TA, et al. # 71
Rasmussen TA, et al. # 71
Rasmussen TA, et al. # 71
Rasmussen TA, et al. # 71
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Ray AS, et al. Antiviral Research 2016
Imaz A, et al. # 478
Imaz A, et al. # 478
Sanford R, et al. # 120
# 425
Perez-Valero I, et al. # 425
Labhardt ND, et al. # 94
Labhardt ND, et al. # 94
Labhardt ND, et al. # 94
Labhardt ND, et al. # 94
Labhardt ND, et al. # 94
69% 43% 50% 34%
Massud I, et al. # 85
Dobard C, et al. # 83
Dobard C, et al. # 83
Dobard C, et al. # 83
Dobard C, et al. # 83
Garber DA, et al. # 82
Garber DA, et al. # 82
Garber DA, et al. # 82
Garber DA, et al. # 82
# 1055
# 88
Grulich A, et al. # 88
Grulich A, et al. # 88
Grulich A, et al. # 88
Grulich A, et al. # 88
Grulich A, et al. # 88
Grulich A, et al. # 88
Grulich A, et al. # 88
Grulich A, et al. # 88
AGRADECIMIENTOS
Charles Dobard
Monica Gandhi
David A Garber
Ivana Massud
Niklaus D Labhardt
Ignacio Perez-Valero
